Phio Pharmaceuticals Corp. (PHIO)
NASDAQ: PHIO · Real-Time Price · USD
2.180
-0.140 (-6.03%)
At close: Sep 12, 2025, 4:00 PM EDT
2.190
+0.010 (0.46%)
After-hours: Sep 12, 2025, 7:27 PM EDT
Phio Pharmaceuticals Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
5
Market Cap
12.48M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | - | - | - |
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | - | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 422.82B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.62B |
AbbVie | 58.33B |
AstraZeneca | 56.50B |
Novartis AG | 55.19B |
Eli Lilly and Company | 53.26B |
Novo Nordisk | 49.11B |
PHIO News
- 10 days ago - Phio Pharmaceuticals to Present at the H.C. Wainwright 27th Annual Global Investment Conference - Newsfile Corp
- 4 weeks ago - Phio Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces Exercise of Warrants for Approximately $2.5 Million Gross Proceeds - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces Pathology Results for Four of Five Patients in Fourth Cohort - Newsfile Corp
- 7 weeks ago - Phio Pharmaceuticals Announces Agreement with U.S. Manufacturing Source for Drug Substance - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces Positive Safety Monitoring Committee Recommendation to Advance INTASYL PH-762 Skin Cancer Clinical Trial to Fifth Dose Escalation Cohort - Newsfile Corp
- 2 months ago - Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series - Newsfile Corp
- 3 months ago - Phio Pharmaceuticals Announces Strategic Initiative to Create Awareness of the Comprehensive INTASYL siRNA Portfolio - Newsfile Corp